Nifty
Sensex
:
:
25291.10
82104.79
146.80 (0.58%)
512.34 (0.63%)

Pharmaceuticals & Drugs - Global

Rating :
74/99

BSE: 533573 | NSE: APLLTD

1057.10
16-Nov-2026
  • Open
  • High
  • Low
  • Previous Close
  •  1033.5
  •  1075
  •  1033.5
  •  1030.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  452099
  •  478595601.55
  •  1075
  •  635.8

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 20,753.13
  • 24.59
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 21,981.37
  • 1.14%
  • 3.49

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 69.87%
  • 0.24%
  • 7.00%
  • FII
  • DII
  • Others
  • 4.55%
  • 14.96%
  • 3.38%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.89
  • 6.72
  • 5.65

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.16
  • 5.04
  • 3.69

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.19
  • 5.31
  • 3.09

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 23.75
  • 29.64
  • 29.49

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.46
  • 3.18
  • 3.53

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.61
  • 17.30
  • 17.96

Earnings Forecasts:

(Updated: 14-11-2026)
Description
2026
2027
2028
2029
Adj EPS
34.33
44.81
51.84
62.01
P/E Ratio
30.79
23.59
20.39
17.05
Revenue
7344.9
9037.6
9779.1
10672.8
EBITDA
1118.47
1590.77
1756.61
2021.48
Net Income
674.77
865.53
1009.67
1204.47
ROA
8.16
10.03
10.98
12.17
P/B Ratio
3.66
3.30
2.95
2.67
ROE
12.42
14.62
15.03
16.61
FCFF
261.08
376.86
754.15
3042.52
FCFF Yield
1.2
1.73
3.46
13.97
Net Debt
1206.92
1169.18
736.02
227.4
BVPS
288.7
319.9
358.8
396.09

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 26
Sep 25
Var%
Jun 26
Jun 25
Var%
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Net Sales
2,603.48
1,910.15
36.30%
2,149.77
1,710.72
25.66%
1,847.72
1,769.64
4.41%
1,876.31
1,692.74
10.84%
Expenses
2,040.21
1,594.46
27.96%
1,817.91
1,429.38
27.18%
1,619.80
1,497.72
8.15%
1,582.81
1,432.52
10.49%
EBITDA
563.27
315.69
78.43%
331.86
281.34
17.96%
227.92
271.92
-16.18%
293.50
260.22
12.79%
EBIDTM
21.64%
16.53%
15.44%
16.45%
12.34%
15.37%
15.64%
15.37%
Other Income
15.11
6.91
118.67%
14.93
6.50
129.69%
25.50
14.19
79.70%
15.50
9.51
62.99%
Interest
38.26
24.23
57.90%
27.61
23.52
17.39%
22.56
24.52
-7.99%
23.31
22.26
4.72%
Depreciation
100.80
76.07
32.51%
97.71
73.77
32.45%
88.59
68.99
28.41%
80.12
70.04
14.39%
PBT
439.32
222.30
97.62%
221.47
190.55
16.23%
117.51
192.60
-38.99%
163.34
177.43
-7.94%
Tax
104.04
40.01
160.03%
49.50
36.47
35.73%
-82.91
35.31
-
29.55
40.08
-26.27%
PAT
335.28
182.29
83.93%
171.97
154.08
11.61%
200.42
157.29
27.42%
133.79
137.35
-2.59%
PATM
12.88%
9.54%
8.00%
9.01%
10.85%
8.89%
7.13%
8.11%
EPS
17.05
9.40
81.38%
8.81
7.85
12.23%
10.31
7.98
29.20%
6.77
7.04
-3.84%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Net Sales
8,477.28
7,344.90
6,672.08
6,228.63
5,652.62
5,305.78
5,393.14
4,605.76
3,934.69
3,130.81
3,134.61
Net Sales Growth
19.68%
10.08%
7.12%
10.19%
6.54%
-1.62%
17.10%
17.06%
25.68%
-0.12%
 
Cost Of Goods Sold
2,366.97
1,984.45
1,793.36
1,715.08
1,708.82
1,446.43
1,257.35
1,039.38
992.71
886.19
887.57
Gross Profit
6,110.31
5,360.45
4,878.72
4,513.55
3,943.80
3,859.35
4,135.79
3,566.38
2,941.98
2,244.62
2,247.04
GP Margin
72.08%
72.98%
73.12%
72.46%
69.77%
72.74%
76.69%
77.43%
74.77%
71.69%
71.68%
Total Expenditure
7,060.73
6,226.90
5,669.16
5,296.00
4,944.56
4,431.64
3,913.05
3,391.69
3,078.87
2,515.55
2,519.90
Power & Fuel Cost
-
177.50
179.69
173.37
151.54
120.84
118.72
102.40
88.86
70.35
64.20
% Of Sales
-
2.42%
2.69%
2.78%
2.68%
2.28%
2.20%
2.22%
2.26%
2.25%
2.05%
Employee Cost
-
1,731.93
1,562.34
1,446.29
1,169.13
1,133.00
1,051.17
906.44
746.69
622.81
558.83
% Of Sales
-
23.58%
23.42%
23.22%
20.68%
21.35%
19.49%
19.68%
18.98%
19.89%
17.83%
Manufacturing Exp.
-
507.61
440.63
387.71
409.37
379.15
372.18
368.41
269.25
244.53
289.79
% Of Sales
-
6.91%
6.60%
6.22%
7.24%
7.15%
6.90%
8.00%
6.84%
7.81%
9.24%
General & Admin Exp.
-
682.47
576.39
525.84
492.64
413.90
391.24
339.82
340.56
283.43
299.79
% Of Sales
-
9.29%
8.64%
8.44%
8.72%
7.80%
7.25%
7.38%
8.66%
9.05%
9.56%
Selling & Distn. Exp.
-
1,083.11
1,064.86
996.88
952.30
890.38
687.41
531.19
590.28
380.21
393.14
% Of Sales
-
14.75%
15.96%
16.00%
16.85%
16.78%
12.75%
11.53%
15.00%
12.14%
12.54%
Miscellaneous Exp.
-
59.83
51.89
50.83
60.76
47.94
34.98
104.05
50.52
28.03
393.14
% Of Sales
-
0.81%
0.78%
0.82%
1.07%
0.90%
0.65%
2.26%
1.28%
0.90%
0.85%
EBITDA
1,416.55
1,118.00
1,002.92
932.63
708.06
874.14
1,480.09
1,214.07
855.82
615.26
614.71
EBITDA Margin
16.71%
15.22%
15.03%
14.97%
12.53%
16.48%
27.44%
26.36%
21.75%
19.65%
19.61%
Other Income
71.04
54.88
47.87
29.04
3.04
50.49
87.48
13.88
27.14
34.87
2.58
Interest
111.74
93.63
78.77
56.19
50.17
17.73
16.02
27.16
18.41
3.40
5.23
Depreciation
367.22
318.55
278.58
272.67
275.43
286.78
183.47
157.32
115.23
105.46
82.97
PBT
941.64
760.70
693.44
632.81
385.50
620.12
1,368.08
1,043.47
749.32
541.27
529.09
Tax
100.18
23.12
125.17
16.01
12.60
104.46
253.32
199.18
156.75
120.36
122.19
Tax Rate
10.64%
3.33%
17.72%
2.53%
3.27%
16.85%
18.52%
19.92%
20.92%
22.24%
23.09%
PAT
841.46
674.77
583.42
615.82
341.99
520.94
1,114.76
828.76
593.65
420.72
406.99
PAT before Minority Interest
845.62
670.83
582.01
615.82
341.99
520.94
1,114.76
800.64
592.57
420.91
406.90
Minority Interest
4.16
3.94
1.41
0.00
0.00
0.00
0.00
28.12
1.08
-0.19
0.09
PAT Margin
9.93%
9.19%
8.74%
9.89%
6.05%
9.82%
20.67%
17.99%
15.09%
13.44%
12.98%
PAT Growth
33.35%
15.66%
-5.26%
80.07%
-34.35%
-53.27%
34.51%
39.60%
41.10%
3.37%
 
EPS
42.80
34.32
29.68
31.32
17.40
26.50
56.70
42.15
30.20
21.40
20.70

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Shareholder's Funds
5,674.81
5,190.94
4,818.20
4,370.47
5,237.54
5,066.98
3,219.42
2,718.83
2,220.14
1,902.33
Share Capital
39.31
39.31
39.31
39.31
39.31
39.31
37.70
37.70
37.70
37.70
Total Reserves
5,635.50
5,151.63
4,778.89
4,331.16
5,198.23
5,027.67
3,181.72
2,681.13
2,182.44
1,864.63
Non-Current Liabilities
230.16
5.05
2.75
52.42
162.07
361.16
1,046.98
570.06
576.20
94.15
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
121.92
0.00
0.00
0.00
0.00
199.89
886.99
499.30
500.00
0.00
Long Term Provisions
152.91
124.31
109.51
106.20
95.82
85.52
74.51
52.03
40.76
57.22
Current Liabilities
2,686.87
2,514.27
1,520.28
1,640.80
1,830.59
1,533.26
1,954.22
1,663.65
1,267.18
813.96
Trade Payables
835.08
879.89
735.64
679.81
706.39
668.78
625.93
644.34
759.32
500.73
Other Current Liabilities
393.96
232.10
223.66
251.19
516.51
557.92
226.98
380.19
142.89
81.28
Short Term Borrowings
1,218.61
1,195.57
430.45
635.87
430.00
0.02
860.50
429.13
207.78
88.51
Short Term Provisions
239.22
206.71
130.53
73.93
177.69
306.54
240.81
209.99
157.19
143.44
Total Liabilities
8,586.01
7,708.84
6,341.23
6,063.69
7,230.20
6,961.40
6,191.66
4,951.75
4,063.83
2,810.55
Net Block
3,080.67
2,523.53
2,546.71
2,398.45
1,797.85
1,788.42
1,551.84
1,158.45
993.38
799.40
Gross Block
4,896.99
4,117.32
3,875.21
3,467.50
2,840.33
2,545.39
2,132.41
1,522.57
1,242.47
950.09
Accumulated Depreciation
1,816.32
1,593.79
1,328.50
1,069.05
1,042.48
756.97
580.57
364.12
249.09
150.69
Non Current Assets
3,920.38
3,519.12
3,197.39
3,149.80
4,255.37
4,056.96
3,526.30
2,820.02
2,116.31
1,316.80
Capital Work in Progress
683.40
837.23
524.36
601.28
2,304.24
2,182.53
1,846.18
1,551.23
1,010.15
396.28
Non Current Investment
140.88
127.21
93.02
96.33
118.40
49.31
17.62
48.76
41.64
49.88
Long Term Loans & Adv.
15.43
31.15
33.30
53.74
34.88
36.70
110.66
61.58
71.14
71.24
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
4,635.63
4,189.72
3,143.84
2,913.89
2,974.83
2,904.44
2,665.36
2,131.73
1,947.52
1,493.75
Current Investments
0.00
0.00
0.00
0.00
0.00
186.97
0.00
0.00
0.00
0.00
Inventories
2,510.65
2,288.14
1,643.54
1,475.27
1,609.70
1,486.15
1,187.54
967.27
733.93
632.75
Sundry Debtors
1,466.30
1,399.79
1,024.84
1,046.41
807.13
348.60
864.75
488.92
526.34
338.82
Cash & Bank
202.70
90.09
126.57
82.27
69.43
105.84
80.75
205.62
89.92
159.60
Other Current Assets
455.98
69.17
59.86
55.32
488.57
776.88
532.32
469.92
597.33
362.58
Short Term Loans & Adv.
375.22
342.53
289.03
254.62
436.92
698.21
504.22
451.71
569.84
355.02
Net Current Assets
1,948.76
1,675.45
1,623.56
1,273.09
1,144.24
1,371.18
711.14
468.08
680.34
679.79
Total Assets
8,556.01
7,708.84
6,341.23
6,063.69
7,230.20
6,961.40
6,191.66
4,951.75
4,063.83
2,810.55

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Cash From Operating Activity
782.73
87.97
803.20
723.94
552.35
1,463.38
449.15
811.97
312.42
328.55
PBT
693.95
707.18
631.83
354.59
625.39
1,368.08
999.82
749.32
541.27
529.09
Adjustment
449.31
373.53
286.87
487.61
417.75
102.42
278.28
117.57
87.12
83.06
Changes in Working Capital
-256.82
-921.36
-95.65
-57.56
-367.36
238.30
-592.84
111.56
-180.85
-165.64
Cash after chg. in Working capital
886.44
159.35
823.05
784.64
675.78
1,708.80
685.26
978.45
447.54
446.51
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-103.71
-71.38
-19.85
-60.70
-123.43
-245.42
-236.11
-166.48
-135.12
-117.96
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-506.06
-568.41
-320.61
-447.59
-371.97
-838.80
-731.63
-755.60
-884.38
-485.91
Net Fixed Assets
-374.17
-554.35
-340.93
994.77
-402.51
-1,311.53
-789.71
-630.35
-606.86
-121.60
Net Investments
-11.84
-32.88
2.59
-9.91
123.73
490.16
-326.86
-207.50
-195.85
-65.58
Others
-120.05
18.82
17.73
-1,432.45
-93.19
-17.43
384.94
82.25
-81.67
-298.73
Cash from Financing Activity
-163.78
443.71
-437.86
-261.96
-217.35
-597.42
154.85
59.03
502.63
-128.88
Net Cash Inflow / Outflow
112.89
-36.73
44.73
14.39
-36.97
27.16
-127.63
115.40
-69.33
-286.24
Opening Cash & Equivalents
83.48
120.21
75.48
61.09
98.06
71.83
199.06
83.74
153.07
439.32
Closing Cash & Equivalent
196.37
83.48
120.21
75.48
61.09
98.06
71.84
199.07
83.74
153.08

Financial Ratios

Consolidated /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Book Value (Rs.)
288.72
264.10
245.14
222.36
266.47
257.80
170.79
144.24
117.78
100.92
ROA
8.23%
8.28%
9.93%
5.15%
7.34%
17.22%
14.64%
13.15%
12.25%
14.97%
ROE
12.35%
11.63%
13.40%
7.12%
10.11%
26.91%
26.97%
24.00%
20.42%
23.25%
ROCE
11.74%
13.51%
13.42%
7.44%
11.25%
26.28%
23.30%
22.66%
22.15%
28.87%
Fixed Asset Turnover
3.16
3.36
1.70
1.79
1.97
2.31
2.52
2.85
2.86
3.07
Receivable days
36.70
32.99
60.69
59.84
39.75
41.06
53.64
47.09
50.43
40.13
Inventory Days
61.45
53.50
91.38
99.60
106.49
90.48
85.38
78.91
79.67
70.01
Payable days
157.72
164.40
150.62
148.04
173.51
187.92
69.87
88.23
98.47
84.03
Cash Conversion Cycle
-59.57
-77.92
1.45
11.40
-27.27
-56.39
69.15
37.76
31.63
26.12
Total Debt/Equity
0.24
0.23
0.09
0.15
0.12
0.10
0.54
0.42
0.32
0.05
Interest Cover
8.41
9.98
12.24
8.07
36.27
86.40
37.81
41.70
160.20
102.16

News Update:


  • Alembic Pharmaceuticals receives USFDA final approval for Binimetinib tablets
    16th Nov 2026, 09:17 AM

    Alembic has a cumulative total of 248 ANDA approvals (230 final approvals and 18 tentative approvals) from the USFDA

    Read More
  • Alembic Pharma - Quarterly Results
    5th Nov 2026, 00:00 AM

    Read More
  • Alembic Pharmaceuticals expands strategic collaboration with DifGen Pharmaceuticals
    4th Nov 2026, 16:12 PM

    DifGen will lead development, regulatory, manufacturing and supply activities, while the company will manufacture select products and commercialise the portfolio in the US

    Read More
  • Alembic Pharmaceuticals gets USFDA’s final nod for Venetoclax Tablets
    31st Oct 2026, 11:20 AM

    Alembic has a cumulative total of 248 ANDA approvals from the USFDA

    Read More
  • Alembic Pharma gets USFDA’s final nod for Valganciclovir for Oral Solution
    28th Oct 2026, 12:58 PM

    Alembic has a cumulative total of 247 ANDA approvals from the USFDA

    Read More
  • Alembic Pharmaceuticals’ arm incorporates subsidiary in Dubai
    21st Oct 2026, 09:59 AM

    The new entity aims to explore new business opportunities and to promote, sale and distribute pharmaceutical product(s) of the company

    Read More
  • Alembic Pharma gets USFDA’s final nod for Ciprofloxacin and Dexamethasone Otic Suspension
    19th Oct 2026, 09:24 AM

    The approved ANDA is therapeutically equivalent to the reference listed drug product, Ciprodex Otic Suspension, 0.3% / 0.1%, of Sandoz Inc

    Read More
  • USFDA completes inspection at Alembic Pharmaceuticals’ Bioequivalence Facility in Vadodara
    11th Sep 2026, 12:50 PM

    The inspection was conducted at the company’s Bioequivalence Facility located in Vadodara and concluded with no Form 483 observations

    Read More
  • Alembic Pharmaceuticals incorporates subsidiary in Dubai
    8th Sep 2026, 10:27 AM

    The new entity has been incorporated to explore new business opportunities and to promote, sale and distribute pharmaceutical product(s) of the company

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.